Hormonal treatment for prostate cancer.
For nearly six decades the preferred primary treatment for advanced prostate cancer has been continuous suppression of testicular androgen production by medical or surgical castration. While androgen deprivation is effective in inducing tumour regression in the large majority of cases, essentially all patients will develop progressive disease. In addition androgen deprivation may be associated with a variety of side effects. Thus, strategies that minimise the use of these agents could potentially lower the morbidity and cost associated with the treatment of advanced prostate cancer. In the era of prostate-specific antigen (PSA) testing, hormonal therapy is being used earlier in the course of the disease when the only evidence of recurrent disease is an elevated PSA. These men may survive for many years and thus have the potential for long periods of exposure to hormonal therapy and its side effects. It has been hoped that the development of alternative hormonal interventions might lead to both enhanced antitumour efficacy as well as improvements in side effect profile.
Harris
K A
KA
UCSF Comprehensive Cancer Center, 1600 Divisadero Street, 3rd Floor, San Francisco, CA 94115, USA.
Small
E J
EJ
D000726:Androgen Antagonists / Q000627:therapeutic use; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal